Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES

SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

Thiele, 2009 - sirolimus ES vs MIDCAB

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES

PASEO, 2009 - drug ES vs bare-metal stent

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

BARI 2D, 2009 - CABG or PCI vs medical treatment

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

Juwana, 2009 - sirolimus ES vs paclitaxel ES

SYNTAX, 2009 - paclitaxel ES vs CABG



See also:

  • All acute myocardial infarction clinical trials
  • All coronary artery disease clinical trials
  • All stable angina clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of sirolimus ES
    		•  

    Di Lorenzo et al. study, 2005

    unpublished (or not yet fully published) trial

    Treatments

    Studied treatment sirolimus
    Control treatment paclitaxel

    Patients

    Patients ST-segment elevation myocardial infarction

    Method and design

    Randomized effectives 90 / 90 (studied vs. control)
    Design Parallel groups
    Blinding open
    Number of centre NA
    Geographic area NA


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    3 / 90
         4 / 90
         classic 0,75 [0,17;3,26]

    MI (fatal and non fatal)

    4 / 90
         3 / 90
         classic 1,33 [0,31;5,79]

    target lesion revascularisation

    3 / 90
         4 / 90
         classic 0,75 [0,17;3,26]

    Stent thrombosis (any, end of follow up)

    0 / 90
         1 / 90
         classic 0,20 [0,00;14,51]

    angiographic restenosis

    NA / 90
         NA / 90

    4y stent thrombosis (ARC)

    0 / 90
         1 / 90
         classic 0,20 [0,00;14,51]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 3 / 90 (3,3%) 4 / 90 (4,4%) 0,75 [0,17;3,26]    
    MI (fatal and non fatal) 4 / 90 (4,4%) 3 / 90 (3,3%) 1,33 [0,31;5,79]    
    Stent thrombosis (any, end of follow up) 0 / 90 (0,6%) 1 / 90 (1,1%) 0,50 [0,02;14,72]    
    4y stent thrombosis (ARC) 0 / 90 (0,6%) 1 / 90 (1,1%) 0,50 [0,02;14,72]    
    target lesion revascularisation 3 / 90 (3,3%) 4 / 90 (4,4%) 0,75 [0,17;3,26]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 3,33% 4,44% -11,1‰
    MI (fatal and non fatal) 4,44% 3,33% 1,1%
    target lesion revascularisation 3,33% 4,44% -11,1‰


    Reference(s)

    unpublished (or not yet fully published) trial

    Trials register # NA
    • Di Lorenzo E, Varricchio A, Lanzillo T, et al.. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr). Circulation 2005;112:U538
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend